Cellipont Bioservices, a cell therapy contract development and manufacturing organization (CDMO), has unveiled plans for a 76,000 square foot commercial-ready manufacturing facility for cell therapies and gene-modified cell therapies. Located in The Woodlands, TX, the facility will include state-of-the-art manufacturing, process development, assay development and testing capabilities redundant with Cellipont’s 26,000 square foot San Diego location. The new facility will be commissioned in phases, with the first phase scheduled to begin operation in the first half of 2023.
